Table 1. Cervical Cancer Screening Guidelines

	American Cancer Society ¹	U. S. Preventive Services Task Force ²	American College of Obstetricians and Gynecologists ³
	(ACS, Nov 2002)	(USPSTF, Jan 2003)	(ACOG, Aug 2003)
When to start	Approximately 3 years after onset of vaginal intercourse, but no later than age 21	Within 3 years of onset of sexual activity or age 21, whichever comes first	Approximately 3 years after onset of sexual intercourse, but no later than age 21
Intervals			
Conventional Pap test	Annually; every 2-3 years for women ≥30 with 3 negative cytology tests*	At least every 3 years	Annually; every 2-3 years for women ≥30 with 3 negative cytology tests*
If liquid-based cytology	Every 2 years; every 2-3 years for women ≥30 with 3 negative cytology tests*	Insufficient evidence	Annually; every 2-3 years for women ≥30 with 3 negative cytology tests*
If HPV testing used**	Every 3 years if HPV negative, cytology negative	Insufficient evidence	Every 3 years if HPV negative, cytology negative
When to stop	Women \geq 70 years with \geq 3 recent, consecutive negative tests & no abnormal tests in prior 10 years*	Women >65 years with negative tests, who are not otherwise at high risk for cervical cancer	Inconclusive evidence to establish upper age limit
Post total hysterectomy	Discontinue if for benign reasons & no prior history of high-grade CIN*	Discontinue if for benign reasons	Discontinue if for benign reasons & no prior history of high-grade CIN*

*Some exceptions apply (e.g., women who are immunocompromised, have a history of prenatal exposure to DES, etc.). See guidelines for details. ** See Table 2 (entitled "Recommendations for Liquid-Based Cytology and HPV Testing") for recommended use.

 ¹ Saslow D, et al. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. CA Cancer J Clin 2002; 52: 342-362. Available at: <u>http://caonline.amcancersoc.org/cgi/content/full/52/6/342</u>
² USPSTF. Screening for Cervical Cancer. Jan 2003. Available at: <u>http://www.ahcpr.gov/clinic/uspstf/uspscerv.htm</u>

³ ACOG. Cervical Cytology Screening. ACOG Practice Bulletin No. 45. ACOG 2003;102: 417-427. See also: http://www.acog.org/from_home/publications/press_releases/nr07-31-03-1.cfm

	American Society for Colposcopy and Cervical Pathology ¹	American Cancer Society ²	U. S. Preventive Services Task Force ³	American College of Obstetricians and Gynecologists ⁴	American Society for Colposcopy and Cervical Pathology, and American Cancer Society ⁵
	(ASCCP, Apr 2002)	(ACS, Nov 2002)	(USPSTF, Jan 2003)	(ACOG, Aug 2003)	(ASCCP & ACS, Feb 2004)
Liquid-based cytology		Option	Insufficient Evidence	Option	
HPV testing					
Women with ASC-US (reflex testing)	Recommended*, Guidance Provided ¹	Option ⁶	Insufficient Evidence	Option	
Women <u>></u> 30 years (adjunct to Pap test)		Option	Insufficient Evidence	Option	Recommended*, Guidance Provided⁵

Table 2. Recommendations for Liquid-Based Cytology and HPV Testing

*Some exceptions apply [e.g., women who are immunosuppressed for any reason, including infection with human immunodeficiency virus (HIV)]

¹ Wright TC, et al. 2001 Consensus Guidelines for the Management of Women with Cervical cytological abnormalities. *JAMA*;2002: 287: 2120-2129. See also: <u>http://www.asccp.org/consensus.shtml</u>

² Saslow D, et al. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. CA Cancer J Clin 2002; 52: 342-362. Available at: http://caonline.amcancersoc.org/cgi/content/full/52/6/342

³ USPSTF. Screening for Cervical Cancer. Jan 2003. Available at: <u>http://www.ahcpr.gov/clinic/uspstf/uspscerv.htm</u>

⁴ ACOG. Cervical Cytology Screening. ACOG Practice Bulletin No. 45. ACOG 2003; 102: 417-427. See also:

http://www.acog.org/from_home/publications/press_releases/nr07-31-03-1.cfm

⁵ Wright TC, et al. Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical cytology for screening. *Obstet Gynecol*. 2004; 103: 304-309.

⁶ ACS. Patient Pages: Early Detection of Cervical Cancer. CA Cancer J Clin, 2002; 52: 375 - 376. See also: <u>http://caonline.amcancersoc.org/cgi/content/full/52/6/375</u>